锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月16日南向资金减持730.8万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持1943.8万股。近20个交易日中，获南向资金减持的有14天，累计净减持3190.0 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.37亿股，占公司已发行普通股的52.09%。 ...

Core Insights - The top three companies with the highest short positions as of January 9 are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.74%, 17.39%, and 16.49% respectively [1][2] - The companies with the largest absolute increase in short positions are Goldwind Technology (02208), Zhaoyan New Drug (06127), and Jingtai Holdings (02228), with increases of 6.84%, 2.14%, and 1.85% respectively [1][2] - The companies with the largest absolute decrease in short positions are COSCO Shipping Energy (01138), Sanhua Intelligent Control (02050), and Huahong Semiconductor (01347), with decreases of -1.77%, -0.80%, and -0.71% respectively [1][3] Top 10 Short Positions - Vanke Enterprises (02202) has a short position of 413 million shares, representing a short ratio of 18.74% [2] - Dongfang Electric (01072) has a short position of 70.93 million shares, with a short ratio of 17.39% [2] - COSCO Shipping Holdings (01919) has a short position of 475 million shares, with a short ratio of 16.49% [2] - Other notable companies in the top 10 include Heng Rui Medicine (01276) at 15.19% and Ping An Insurance (02318) at 14.74% [2] Largest Increases in Short Positions - Goldwind Technology (02208) saw its short ratio increase from 4.35% to 11.18%, an increase of 6.84% [2] - Zhaoyan New Drug (06127) increased from 6.65% to 8.79%, an increase of 2.14% [2] - Jingtai Holdings (02228) increased from 3.34% to 5.19%, an increase of 1.85% [2] Largest Decreases in Short Positions - COSCO Shipping Energy (01138) decreased from 7.11% to 5.34%, a decrease of -1.77% [3] - Sanhua Intelligent Control (02050) decreased from 6.52% to 5.72%, a decrease of -0.80% [3] - Huahong Semiconductor (01347) decreased from 4.85% to 4.13%, a decrease of -0.71% [3]

锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月15日南向资金减持278.45万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持1349.4万股。近20个交易日中，获南向资金减持的有13天，累计净减持2050.9 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.44亿股，占公司已发行普通股的52.35%。 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.67 million shares on January 7, with a total net reduction of 7.017 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have reduced their holdings on 14 days, resulting in a cumulative net reduction of 29.177 million shares [1] - As of now, southbound funds hold 1.456 billion shares of Jinxin Reproductive Medicine, accounting for 52.78% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Major Events - Brain动极光-B (06681) signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center [1] - Cohere New Energy (00182) successfully completed a secondary listing on the Singapore Stock Exchange [1] - Bole康视云-B (02592) submitted a clinical trial application for the new drug CBT-009 to the Drug Evaluation Center [1] - Yingtong Holdings (06883) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its high-end fragrance distribution network in China [1] - Weimeng Group (02013) initiated a business cooperation with Taobao Flash Purchase [1] - Dali普控股 (01921) officially became a qualified supplier for Saudi Aramco [1] - Yiming Anke-B (01541) regained global rights for IMM2510 and IMM27M [1] - Yuexiu Property (00123) subsidiary Shanghai Yuheng won a land parcel in Shanghai's Pudong New District [1] Operating Performance - Jinxin Reproductive (01951) reported a further narrowing of the overall decline in IVF egg retrieval cycles to -1.4% for 2025 [1] - Poly Real Estate Group (00119) achieved a cumulative contract sales amount of approximately 50.2 billion yuan for 2025, a year-on-year decrease of 7.38% [1] - Yadea Holdings (01585) issued a profit warning, expecting annual net profit to be no less than 2.9 billion yuan [1] - Jindi Commercial Real Estate (00535) reported a cumulative contract sales total of approximately 10.696 billion yuan for 2025, a year-on-year decrease of 47.33% [1] - Greentown Management Holdings (09979) estimated the construction fee for newly developed projects in 2025 to be 9.35 billion yuan, a year-on-year increase of approximately 0.4% [1] - Sunac China (01918) achieved a cumulative contract sales amount of approximately 36.84 billion yuan for 2025, a year-on-year decrease of 21.85% [1]

Core Viewpoint - The company, Jinxin Reproductive, has demonstrated continuous operational improvement in Q4, with a notable reduction in the year-on-year decline of IVF egg retrieval cycles from 5.2% in the previous three quarters to 1.4% by the end of 2025, indicating strong business resilience [1][3]. Group 1: Operational Performance - The Greater China region has benefited from ongoing optimization in market expansion, operational efficiency, and customer service, showcasing significant business resilience [1][3]. - The flagship IVF center in Chengdu has shown a remarkable improvement, with the year-on-year decline in egg retrieval cycles decreasing from -1.9% in the previous three quarters to a growth of 1.3% for the entire year of 2025 [1][3]. - The incubation centers have further improved, achieving a year-on-year growth of 1.5% in egg retrieval cycles [1][3]. - In overseas markets, despite the impact of the delay in the U.S. reproductive health coverage legislation SB729, the decline in cycle numbers has also narrowed [1][3]. Group 2: Strategic Developments - Jinxin Reproductive plans to complete the relocation of the Shenzhen Zhongshan Maternal and Child Health Hospital by early 2026, establishing a southern headquarters that will increase the hospital's area by seven times, enhancing service capacity, research capabilities, and overall strength [2][4]. - The southern headquarters, centered around the Shenzhen Zhongshan Maternal and Child Health Hospital, is positioned to lead in research capabilities within the industry, having published over 30 SCI papers in 2025, with more than 500 citations, and secured seven national and provincial research projects [2][4].

Group 1 - The core viewpoint of the articles indicates that despite a decline in performance in the first half of 2025 compared to the same period in 2024, the company shows resilience in its operations, with a slight overall decrease in annual performance compared to 2024 [1] - The number of IVF cycles in the Greater China region is expected to improve, with a reduction in the decline from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025 [1] - The flagship hospital in Chengdu has shown significant improvement, with IVF cycles turning from a decline of -1.9% in the first three quarters of 2025 to a growth of 1.3% for the entire year [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to deepen research innovation and clinical translation in reproductive medicine, optimize medical processes, and improve digital service experiences [2] - The company will leverage national fertility support policies and industry development opportunities to strengthen its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]

Group 1 - The core viewpoint of the articles highlights that the company, Jinxin Reproductive Medicine (01951), has shown resilience in its IVF cycle numbers, with a projected improvement in Q4 2025 compared to Q3 2025, despite an 8.0% decline in H1 2025 compared to H1 2024 [1] - The overall decline in IVF cycles has narrowed from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025, indicating a recovery trend [1] - The flagship hospital in Chengdu has seen a turnaround, with IVF cycles growing by 1.3% in 2025 compared to a decline of -1.9% in the first three quarters of 2025 [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels, while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to strengthen its market position in Chengdu and expand its capacity in the Greater Bay Area following the relocation of new facilities, while also addressing overseas policy changes to tap into international market growth potential [2] - The company intends to leverage national fertility support policies and industry development opportunities to solidify its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]

下表載列本集團自有醫院和投資－營運－移交（「IOT」）協議或管理服務協議（「MSA」）1 管 理的醫院及診所於截至2025年12月31日止年度及截至2025年9月30日止九個月的IVF取卵 周期數，連同2024年同期的比較數據： Jinxin Fertility Group Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 1951 * 自願公告 2025年第四季度的主要營運數據 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發，旨在使本公司股東及潛在 投資者了解本公司及其附屬公司（「本集團」）的最新業務進展。 本公司董事會（「董事會」）欣然宣佈，通過持續不斷的優化運營措施，於2025年第四季 度，本集團的體外受精（「IVF」）取卵周期數較2025年第三季度有了進一步提升。儘管2025 年上半年業績較2024年同期下滑8.0%，但本集團2025年大中華區業務仍展現出強勁韌 性，全年業績相較2024年僅微降0.4%，已基本回升至 ...

致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025 ...